Unveiling the tendon toxicity spectrum of anastrozole, letrozole, and exemestane: a real-world pharmacovigilance study - Top-Institutions - MDSpire

Unveiling the tendon toxicity spectrum of anastrozole, letrozole, and exemestane: a real-world pharmacovigilance study

  • By

  • Shuai Zhao

  • Lu-Yao Xu

  • Ping Chen

  • Su Zhang

  • Kai-Li Mao

  • July 7, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

Original Source(s)

Unveiling the tendon toxicity spectrum of anastrozole, letrozole, and exemestane: a real-world pharmacovigilance study

  • by Shuai Zhao, Lu-Yao Xu, Ping Chen, Su Zhang, Kai-Li Mao

  • July 7, 2026

Related Content

Differences in Cascade Genetic Testing Among Families With Hereditary Cancer Risk

Isoflavones impair anti-PD1 efficacy in breast cancer, regardless of dietary fiber or fecal short-chain fatty acid levels

Beyond the physician shortage: infrastructure as a rate-limiting step in breast cancer care